Protocol Ledger

NCT06976944 · Phase II · RECRUITING

Pembrolizumab + Paclitaxel +/- Bevacizumab for Triple-negative Breast Cancer

Interventional Phase II clinical trial protocol NCT06976944 sponsored by Yukinori Ozaki in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-06-24 Enrollment: 24 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06976944
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)24 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06976944
Protocol FieldVerified Registry Value
NCT IdentifierNCT06976944
Consolidated Lead SponsorYukinori Ozaki
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment24 participants (ESTIMATED)
Registered Start Date2025-06-24
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06976944
Hospital Research SiteLocationSite Profile
Nagoya University HospitalNagoya, JapanOpen Hospital Dossier ->
Nagoya City University HospitalNagoya, JapanOpen Hospital Dossier ->
Hiroshima University HospitalHiroshima, JapanOpen Hospital Dossier ->
Hokkaido University HospitalSapporo, JapanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI